Texas biotech ZS Pharma banked a $55 million D round, cash that should help get its Phase III-tested treatment into the hands of regulators and, eventually, onto the market.
Anyone looking to start a biotech company should pay close attention to this list. Venture groups, entrepreneurs and increasingly Big Pharma have been concentrating their money and their attention in a few key places, only occasionally straying from the beaten path when funding a high-risk drug development effort.
Days after word got out that Abingworth was nigh on closing its latest raise, the London-based venture capital stalwart has signed the final line on an upsized $375 million fund. Now, after coming through with some high-profile exits in recent years, Managing Partner Stephen Bunting said his firm is looking for the next generation of biotech winners.
Life sciences venture outfit Abingworth is creeping up on a close for its 6th fund, according to Dow Jones Venturewire, reportedly outstripping its goal of $330 million as it stocks up for another round of investments.
Novo Ventures has stepped up to lead a $49 million round for San Diego-based Thesan Pharmaceuticals, which is developing new dermatology drugs for conditions like acne and atopic dermatitis.
On the same day it announced a $55 million E round, California biotech Versartis filed to go public in an $80 million IPO, planning to use its fast-growing bank account to get a promising orphan therapy through late-stage trials.
Swiss biotech Novimmune has closed a $66 million B round to bankroll its broad pipeline of monoclonal antibodies, and one of the company's lead investors told a local newspaper that it's considering going public to further finance its projects.
Tokyo drug developer RegImmune has banked $9.2 million in Series D financing to bankroll early-stage products using the company's immune system-regulating platform.
I've been in the U.K. for a few days now, grabbing some meetings along the way after discussing valuations in biotechnology with a group of One Nucleus members at The Babraham Institute near Cambridge. And I've been thinking about this question a lot this week.
Third Rock Ventures has cut the ribbon on its latest startup, pledging $45 million to launch Cambridge, MA's Voyager Therapeutics, a gene therapy biotech with a promising platform for central nervous system treatments.